- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: 47H4 v5 hulgG1  | MEMP1972A | RG-7449
Compound class: Antibody
Comment: Quilizumab is a humanized IgG1κ investigational monoclonal antibody designed to bind the M1' segment of membrane-bound immunoglobulin E (mIgE), which is part of the B-cell receptor (BCR) on B cells .
Peptide sequences and 3D structural information for this antibody are available from its IMGT/mAb-DB record.
BLAST peptide analysis reveals 100% matches with sequences claimed in patent US8071097 B2 .
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
1. Gauvreau GM, Harris JM, Boulet LP, Scheerens H, Fitzgerald JM, Putnam WS, Cockcroft DW, Davis BE, Leigh R, Zheng Y et al.. (2014)
Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production.
Sci Transl Med, 6 (243): 243ra85. [PMID:24990880]
2. Kolkhir P, Altrichter S, Munoz M, Hawro T, Maurer M. (2020)
New treatments for chronic urticaria.
Ann Allergy Asthma Immunol, 124 (1): 2-12. [PMID:31446134]
3. Pennington LF, Gasser P, Brigger D, Guntern P, Eggel A, Jardetzky TS. (2021)
Structure-guided design of ultrapotent disruptive IgE inhibitors to rapidly terminate acute allergic reactions.
J Allergy Clin Immunol, [Epub ahead of print]. DOI: 10.1016/j.jaci.2021.03.050 [PMID:33991582]
4. Wu L, Balazs M, Brightbill H, Chan A, Chen Y, Chuntharapai A, Dennis M, Wong T. (2011)
Apoptotic anti-IgE antibodies.
Patent number: US8071097 B2. Assignee: Genentech, Inc.. Priority date: 22/03/2007. Publication date: 06/12/2011.